CA3266274A1 - Combination therapies for the treatment of T-cell lymphoma with tolinapant, cedazuridine, and decitabin - Google Patents

Combination therapies for the treatment of T-cell lymphoma with tolinapant, cedazuridine, and decitabin

Info

Publication number
CA3266274A1
CA3266274A1 CA3266274A CA3266274A CA3266274A1 CA 3266274 A1 CA3266274 A1 CA 3266274A1 CA 3266274 A CA3266274 A CA 3266274A CA 3266274 A CA3266274 A CA 3266274A CA 3266274 A1 CA3266274 A1 CA 3266274A1
Authority
CA
Canada
Prior art keywords
tolinapant
cedazuridine
decitabine
treatment
combination therapies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3266274A
Other languages
English (en)
French (fr)
Inventor
Martin John Sims
George Albert Ward
Harold Keer
Aram Oganesian
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of CA3266274A1 publication Critical patent/CA3266274A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3266274A 2022-08-31 2022-11-04 Combination therapies for the treatment of T-cell lymphoma with tolinapant, cedazuridine, and decitabin Pending CA3266274A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263374137P 2022-08-31 2022-08-31
US63/374,137 2022-08-31
PCT/IB2022/060652 WO2024047394A1 (en) 2022-08-31 2022-11-04 Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine

Publications (1)

Publication Number Publication Date
CA3266274A1 true CA3266274A1 (en) 2024-03-07

Family

ID=84359488

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3266274A Pending CA3266274A1 (en) 2022-08-31 2022-11-04 Combination therapies for the treatment of T-cell lymphoma with tolinapant, cedazuridine, and decitabin

Country Status (9)

Country Link
US (1) US20240082286A1 (https=)
EP (1) EP4580635A1 (https=)
JP (1) JP2025529240A (https=)
KR (1) KR20250053870A (https=)
AU (1) AU2022476674A1 (https=)
CA (1) CA3266274A1 (https=)
MX (1) MX2025002312A (https=)
TW (1) TW202410893A (https=)
WO (1) WO2024047394A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)
US12239653B2 (en) * 2020-02-25 2025-03-04 Taiho Pharmaceutical Co., Ltd. Combination decitabine and cedazuridine solid oral dosage forms

Also Published As

Publication number Publication date
TW202410893A (zh) 2024-03-16
US20240082286A1 (en) 2024-03-14
WO2024047394A1 (en) 2024-03-07
JP2025529240A (ja) 2025-09-04
KR20250053870A (ko) 2025-04-22
AU2022476674A1 (en) 2025-04-17
MX2025002312A (es) 2025-04-02
EP4580635A1 (en) 2025-07-09

Similar Documents

Publication Publication Date Title
WO2020191326A8 (en) Treatment of acute myeloid leukemia (aml) with venetoclax failure
CA3254506A1 (en) POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING TOO MUCH -2
CA3266274A1 (en) Combination therapies for the treatment of T-cell lymphoma with tolinapant, cedazuridine, and decitabin
CA3266672A1 (en) POLYTHERAPY
HK40129584A (en) Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine
WO2022053993A3 (en) Treatments for sars-cov-2 infection (covid-19)
MX2024005589A (es) Combinaciones de lurbinectedina y atezolizumab.
AU2024217542A1 (en) Combination therapy and related methods
CA3262869A1 (en) TREATMENT OF ACUTE ORGANIC INJURY USING CD39, RECOMINENT CD39
CA3261397A1 (en) POLYTHERAPY
EP4295386A4 (en) SEQUENTIAL PLASMA AND HEAT TREATMENT
EP4178359A4 (en) COMBINATION THERAPIES FOR THE TREATMENT AND PREVENTION OF BIOFILMS
EP4004013A4 (en) DINUCLEOTIDE COMPOUNDS FOR THE TREATMENT OF CANCER AND THEIR MEDICAL USES
EP4252586B8 (en) Fireproof cabinet body structure and fireproof safety cabinet
CA3291230A1 (en) Macrophage signatures for diagnostic and therapeutic methods for lymphoma
HK40057269A (en) Adeno-associated viruses and their uses for inner ear therapy
CA3280258A1 (en) Combination therapy and related methods
HK40130925A (zh) 组合疗法及相关方法
HK40117572A (en) Methods for treating peripheral t-cell lymphoma
CA3274673A1 (en) Treating pain associated with peripheral neuropathies
HK40072864A (en) Depletion regimes for engineered t-cell or nk-cell therapy
HK40113850A (en) Inhibitors of molluscum contagiosum infection and methods using the same
CA3300403A1 (en) Combination therapy and uses thereof
AU2023902434A0 (en) Combination therapy and uses thereof
CA3263205A1 (en) MEDICAL DEVICE INTRODUCERS, THEIR MANUFACTURING PROCESSES AND THEIR STERILIZATION PROCESSES

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20250227

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250529

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250529

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250529

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250529

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250926

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250926